WO2004051281A1 - ペプチドのc末端アミノ酸配列解析方法 - Google Patents
ペプチドのc末端アミノ酸配列解析方法 Download PDFInfo
- Publication number
- WO2004051281A1 WO2004051281A1 PCT/JP2003/015270 JP0315270W WO2004051281A1 WO 2004051281 A1 WO2004051281 A1 WO 2004051281A1 JP 0315270 W JP0315270 W JP 0315270W WO 2004051281 A1 WO2004051281 A1 WO 2004051281A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- amino acid
- reaction
- acid
- gel
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 305
- 125000001433 C-terminal amino-acid group Chemical group 0.000 title claims abstract description 168
- 238000000034 method Methods 0.000 title claims abstract description 128
- 238000006243 chemical reaction Methods 0.000 claims abstract description 165
- 238000011282 treatment Methods 0.000 claims abstract description 119
- 239000002253 acid Substances 0.000 claims abstract description 116
- 239000007795 chemical reaction product Substances 0.000 claims abstract description 78
- 239000000126 substance Substances 0.000 claims abstract description 48
- 239000000203 mixture Substances 0.000 claims abstract description 42
- 150000008065 acid anhydrides Chemical class 0.000 claims abstract description 40
- 239000000010 aprotic solvent Substances 0.000 claims abstract description 35
- DQRFCVHLNUNVPL-UHFFFAOYSA-N 2h-1,3-oxazol-5-one Chemical group O=C1OCN=C1 DQRFCVHLNUNVPL-UHFFFAOYSA-N 0.000 claims abstract description 25
- 238000001502 gel electrophoresis Methods 0.000 claims abstract description 23
- 230000007423 decrease Effects 0.000 claims abstract description 6
- 150000008064 anhydrides Chemical class 0.000 claims description 84
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 58
- 150000001413 amino acids Chemical class 0.000 claims description 55
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 51
- 239000003153 chemical reaction reagent Substances 0.000 claims description 44
- 238000000354 decomposition reaction Methods 0.000 claims description 43
- 238000006297 dehydration reaction Methods 0.000 claims description 43
- 208000005156 Dehydration Diseases 0.000 claims description 42
- 239000003880 polar aprotic solvent Substances 0.000 claims description 42
- 239000011259 mixed solution Substances 0.000 claims description 39
- 238000004949 mass spectrometry Methods 0.000 claims description 36
- 125000003277 amino group Chemical group 0.000 claims description 33
- 239000007864 aqueous solution Substances 0.000 claims description 32
- 230000018044 dehydration Effects 0.000 claims description 31
- -1 nitrogen-containing aromatic ring compound Chemical class 0.000 claims description 31
- 239000002904 solvent Substances 0.000 claims description 29
- 210000004899 c-terminal region Anatomy 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 26
- 230000006181 N-acylation Effects 0.000 claims description 22
- 125000000539 amino acid group Chemical group 0.000 claims description 21
- 238000007865 diluting Methods 0.000 claims description 21
- 125000004432 carbon atom Chemical group C* 0.000 claims description 19
- 230000008569 process Effects 0.000 claims description 19
- 238000000926 separation method Methods 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 12
- 229920002401 polyacrylamide Polymers 0.000 claims description 11
- 238000005917 acylation reaction Methods 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 230000008961 swelling Effects 0.000 claims description 9
- 238000001962 electrophoresis Methods 0.000 claims description 8
- 238000004090 dissolution Methods 0.000 claims description 7
- 238000012545 processing Methods 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 238000010790 dilution Methods 0.000 claims description 5
- 239000012895 dilution Substances 0.000 claims description 5
- 239000003125 aqueous solvent Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 claims description 2
- 239000013585 weight reducing agent Substances 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 abstract description 34
- 230000007017 scission Effects 0.000 abstract description 34
- 239000007788 liquid Substances 0.000 abstract description 9
- 238000007086 side reaction Methods 0.000 abstract description 9
- 238000006731 degradation reaction Methods 0.000 abstract description 8
- 230000015556 catabolic process Effects 0.000 abstract description 6
- 230000000593 degrading effect Effects 0.000 abstract 2
- 229940024606 amino acid Drugs 0.000 description 57
- 235000001014 amino acid Nutrition 0.000 description 56
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 50
- 125000003275 alpha amino acid group Chemical group 0.000 description 40
- 239000000523 sample Substances 0.000 description 40
- 102000004142 Trypsin Human genes 0.000 description 28
- 108090000631 Trypsin Proteins 0.000 description 28
- 239000012588 trypsin Substances 0.000 description 28
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 24
- 102000007079 Peptide Fragments Human genes 0.000 description 24
- 108010033276 Peptide Fragments Proteins 0.000 description 24
- 238000006640 acetylation reaction Methods 0.000 description 23
- 238000006460 hydrolysis reaction Methods 0.000 description 23
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 22
- 230000029087 digestion Effects 0.000 description 20
- 230000007062 hydrolysis Effects 0.000 description 20
- 102000004196 processed proteins & peptides Human genes 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- 238000013467 fragmentation Methods 0.000 description 19
- 238000006062 fragmentation reaction Methods 0.000 description 19
- 230000036961 partial effect Effects 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 102000018146 globin Human genes 0.000 description 17
- 108060003196 globin Proteins 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 239000012634 fragment Substances 0.000 description 15
- 102000035195 Peptidases Human genes 0.000 description 14
- 108091005804 Peptidases Proteins 0.000 description 14
- 239000004365 Protease Substances 0.000 description 14
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 14
- 238000005259 measurement Methods 0.000 description 14
- 102400000107 C-terminal peptide Human genes 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 239000007806 chemical reaction intermediate Substances 0.000 description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 13
- 150000002500 ions Chemical class 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 241000894007 species Species 0.000 description 13
- 108010062374 Myoglobin Proteins 0.000 description 12
- 102000036675 Myoglobin Human genes 0.000 description 12
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 11
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 10
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 210000004900 c-terminal fragment Anatomy 0.000 description 9
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 9
- 239000011148 porous material Substances 0.000 description 9
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 8
- 238000003277 amino acid sequence analysis Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 8
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical group O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- UFFSXJKVKBQEHC-UHFFFAOYSA-N heptafluorobutyric anhydride Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(=O)OC(=O)C(F)(F)C(F)(F)C(F)(F)F UFFSXJKVKBQEHC-UHFFFAOYSA-N 0.000 description 7
- 230000009257 reactivity Effects 0.000 description 7
- 108091028026 C-DNA Proteins 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 150000007530 organic bases Chemical class 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 6
- 101800001415 Bri23 peptide Proteins 0.000 description 5
- 101800000655 C-terminal peptide Proteins 0.000 description 5
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000010517 secondary reaction Methods 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 150000007960 acetonitrile Chemical class 0.000 description 4
- 230000021736 acetylation Effects 0.000 description 4
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000008684 selective degradation Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 101100518501 Mus musculus Spp1 gene Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 238000011033 desalting Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- 238000006317 isomerization reaction Methods 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000007030 peptide scission Effects 0.000 description 3
- YPJUNDFVDDCYIH-UHFFFAOYSA-N perfluorobutyric acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)F YPJUNDFVDDCYIH-UHFFFAOYSA-N 0.000 description 3
- 238000012805 post-processing Methods 0.000 description 3
- 238000007781 pre-processing Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical group OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- LRMSQVBRUNSOJL-UHFFFAOYSA-N 2,2,3,3,3-pentafluoropropanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)F LRMSQVBRUNSOJL-UHFFFAOYSA-N 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 230000006179 O-acylation Effects 0.000 description 2
- 241000364051 Pima Species 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 125000002587 enol group Chemical group 0.000 description 2
- 230000006862 enzymatic digestion Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000007792 gaseous phase Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000012846 protein folding Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- XETRHNFRKCNWAJ-UHFFFAOYSA-N 2,2,3,3,3-pentafluoropropanoyl 2,2,3,3,3-pentafluoropropanoate Chemical compound FC(F)(F)C(F)(F)C(=O)OC(=O)C(F)(F)C(F)(F)F XETRHNFRKCNWAJ-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000008015 Hemeproteins Human genes 0.000 description 1
- 108010089792 Hemeproteins Proteins 0.000 description 1
- 101000635854 Homo sapiens Myoglobin Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- VEYYWZRYIYDQJM-ZETCQYMHSA-N N(2)-acetyl-L-lysine Chemical group CC(=O)N[C@H](C([O-])=O)CCCC[NH3+] VEYYWZRYIYDQJM-ZETCQYMHSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 238000006954 Reich reaction Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 238000007171 acid catalysis Methods 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000012993 chemical processing Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- VUVZASHBYYMLRC-UHFFFAOYSA-N heptane-2,3-diol Chemical compound CCCCC(O)C(C)O VUVZASHBYYMLRC-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000006462 rearrangement reaction Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6818—Sequencing of polypeptides
- G01N33/6821—Sequencing of polypeptides involving C-terminal degradation
Definitions
- the present invention relates to a method for analyzing a C-terminal amino acid sequence of a peptide, and more specifically, separation by gel electrophoresis of a protein comprising a peptide chain of at least 50 amino acids or more, usually 100 amino acids or more.
- the C-terminal amino acid of the peptide is sequentially decomposed by a chemical method while being supported on the gel carrier, and the molecular weight of the reaction product is determined by mass spectrometry.
- the present invention relates to a method for elucidating a C-terminal amino acid sequence based on a decrease in molecular weight caused by a series of amino acids sequentially removed. Background art
- Identification of amino acid sequences of peptides and proteins collected from nature is indispensable information when studying the biological properties and functions of powerful peptides and proteins.
- the entire amino acid sequence of peptides and proteins is based on the corresponding genetic information, that is, the amino acid deduced based on the genomic gene encoding these peptides and the nucleotide sequence of c_DNA prepared from m_RNA. It is determined as an array.
- knowledge of partial amino acid sequence of the peptide is still necessary for specifying genomic gene encoding the peptide and c-DNA prepared from m-RNA.
- the N-terminal amino acid sequence and the C-terminal amino acid sequence of the peptide are considered to be particularly useful.
- the target c-DNA is selected using the prepared nucleic acid probe based on the amino acid sequences at both ends. It is possible to do.
- it is also possible to selectively amplify a target c_DNA by applying a PCR method using oligonucleotide primers prepared based on the amino acid sequences at both ends.
- a method has been proposed for effecting the selective degradation of the C-terminal amino acid promoted by anhydride (Tsugita, A. eta 1., Chem. Lett.
- the above selective decomposition reaction of the C-terminal amino acid proceeds sequentially, and after a predetermined processing time has elapsed, 1 to 10 amino acid residues are removed from the C-terminal of the original peptide, respectively.
- a mixture containing the series of reaction products obtained is obtained.
- mass spectrometry By applying mass spectrometry to the mixture containing this series of reaction products and measuring the mass of the ion species derived from each reaction product, a series of mass differences that reflect the c-terminal amino acid sequence are shown. The peak can be measured.
- each reaction product is generated by a sequential C-terminal amino acid degradation reaction from the original peptide, resulting in several types of reaction products, for example, a reaction product in which several amino acid residues have been removed from the original peptide.
- mass of the corresponding ion species can be analyzed collectively.
- the C-terminal amino acid sequence of such several amino acid residues can be determined at a time.
- information on the c-terminal amino acid sequence used for preparing a nucleic acid probe or primer is usually about 18 to 24 bases long as a base sequence encoding a powerful amino acid sequence. It may be up to about 8 amino acids, and it is only necessary in very special cases to elucidate the C-terminal amino acid sequence that reaches 10 amino acid residues.
- the method of applying these perfluoroalkanoic acid or perfluoroalkanoic anhydride vapors to the dried peptide while supplying them from the gas phase is a useful means for elucidating the C-terminal amino acid sequence. Because the reaction uses a reaction reagent supplied from the gas phase, the peptide sample to be analyzed is isolated and purified, and then dried to obtain a pure peptide, and then analyzed. Means had been applied. Accordingly, the availability of a pure peptide product after isolation and purification beforehand has been a prerequisite for the application of the analytical method utilizing a reaction reagent supplied from such a gas phase.
- the amino acid sequence was collected from a specific cell tissue.
- a method of separating a mixed sample containing a large number of peptides and proteins by gel electrophoresis for example, in the SDS-PAGE method, a spot corresponding to the molecular weight is shown on a polyacrylamide gel carrier.
- Techniques for confirming the presence of peptides and proteins are widely used.
- peptides and proteins are isolated as two-dimensionally subdivided spots according to the difference in molecular weight / isoelectric point. At that time, it is necessary to verify whether the peptide giving the spot detected on the gel carrier is actually the target peptide.
- a method of reacting an antibody showing specific reactivity with the target peptide and detecting the presence or absence of the antigen / antibody reaction is performed. Is used. However, this verification method is only applicable when antibodies with specific reactivity are available.
- a verification method using a method called a peptide “mass” fingerprint (PMF) method is also used.
- PMF peptide “mass” fingerprint
- This PMF method is used when the molecular weight of each of the generated peptide fragments is known in advance when the target peptide is enzymatically digested with a protease having specificity at the cleavage site, for example, trypsin.
- the isolated peptide is fragmented by the same enzymatic digestion, and the molecular weight of each peptide fragment is measured using mass spectrometry, and compared with the individual molecular weights of the peptide fragments recorded in the database. Then, the identity is verified.
- the present inventors have already determined the amino acid sequence. For known peptides and proteins, separation by gel electrophoresis under the same conditions will result in unique positions. In order to give spots with considerable reproducibility, analyze the partial amino acid sequence of the peptide generating the spot at the corresponding position, and verify whether it matches the corresponding partial sequence in the known amino acid sequence It was conceived that alternative means would be available. More specifically, for example, when using the SDS-PAGE method or the two-dimensional electrophoresis method, the approximate molecular weight of the band or the peptide giving the spot detected on the gel carrier is known.
- an object of the present invention is to provide a peptide to be analyzed separated by gel electrophoresis, specifically, a peptide chain having a large number of amino acid residues such as a protein.
- the C-terminal amino acid is successively degraded using a reaction mechanism via formation of an oxazolone ring structure while the peptide is supported on a gel carrier, the peptide bond in the middle of the peptide
- An object of the present invention is to provide a means for sequentially decomposing C-terminal amino acid, which can suppress undesired side reactions such as rupture, and at the same time, can perform such chemical treatment itself under versatile conditions. is there.
- an object of the present invention is to remove the water contained in the gel-like substance while supporting it on a gel carrier, dry the peptide, and then sequentially remove its C-terminal amino acid.
- a peptide that stays in the pore structure of the inner part of the gel can be uniformly supplied with a reagent that performs such chemical treatment, and a new sequential method that can be performed under mild conditions near room temperature. It is an object of the present invention to provide a method for analyzing a peptide C-terminal amino acid sequence using a means for decomposing C-terminal amino acid.
- the gel-like substance used in the gel electrophoresis has a fine hole structure through which a peptide can pass.
- a reaction is performed to form an oxazolone ring structure in a state of being impregnated with water, it is necessary to remove water impregnated in the gel-like substance.
- the water molecules filling the fine hole structure are removed, resulting in a reduction in the bulk volume of the entire gel, and the reaction reagent is vaporized as a vapor inside the narrow fine hole structure. It was difficult to supply to.
- the present inventors further studied a method of supplying a reaction reagent, and found that a gel having a narrow internal fine pore structure formed by dehydration operation was free from water, and was not subjected to perfluoroal carboxylic acid or acid anhydride. Swelling again by using an organic solvent capable of dissolving the reaction reagents such as the above, to widen the gap of the internal fine hole structure, and gel the reaction reagent dissolved in the organic solvent through the gap. It has been found that it is possible to supply evenly to the inside.
- the gel carrier is immersed in the mixture to cause alkanoic anhydride and perfluoroalkanoic acid to act on the peptide sample of interest in a supported state, thereby forming an oxazolone ring structure at the C-terminus.
- the present inventors have found that a series of reactions of dissociation of terminal amino acid residues and formation of an oxazolone ring structure can be carried out.
- Both the peptide and the original peptide do not diffuse or elute in the gel swollen with a strong dipolar aprotic solvent, and are maintained on the gel carrier without mass. Check that it is possible to analyze simultaneously by precipitation, was led to you completed the present invention.
- the method for analyzing the C-terminal amino acid sequence of a peptide according to the present invention is a method for analyzing the C-terminal amino acid sequence of a peptide to be analyzed. Preparing a mixture containing a series of reaction products obtained by sequentially decomposing the C-terminal amino acid,
- the target peptide supported on the gel carrier At a temperature selected from the range of 30 ° C. to 80 ° C.
- R 1 represents the side chain of the C-terminal amino acid of the peptide
- R 2 represents a side chain of an amino acid residue located immediately before the C-terminal amino acid) through a 5-oxazolone structure represented by the following formula: Performing a sequential decomposition of the amino acid;
- the mixed solution used for the sequential decomposition reaction of the C-terminal amino acid is mixed with the perfluoroalkanoic acid and the alkanoic acid anhydride and the dipolar aprotic solvent without causing the gel-like substance to be dissolved.
- a peptide sample of interest having a step of terminating the decomposition reaction and removing the reaction reagent by diluting and removing with a polar aprotic solvent having affinity for It is done by the method of processing in the state of being carried,
- the carbon number is 2 to 4
- the symmetrical M anhydride of the alkanoic acid it is more preferable to use a symmetrical acid anhydride of a straight-chain alnic acid having 2 to 4 carbon atoms as the symmetrical acid anhydride of the arnic acid having 2 to 4 carbon atoms.
- acetic anhydride as the alkanoic anhydride contained in the mixed solution obtained by dissolving the perfluoroalkanoic acid in a small amount ratio to the arnic acid anhydride.
- pK represented by the perfluoroalkanoic acid is used as the perfluoroalkanoic acid contained in the mixed solution obtained by dissolving the perfluoroalkanoic acid in a small ratio with respect to the arnic anhydride.
- a is preferably a perfluoroalkanoic acid in the range of 0.3 to 2.5.
- perfluoroalkanoic acid having 2 to 4 carbon atoms may be used as a perfluoroalkanoic acid contained in a mixed solution obtained by dissolving the perfluoroalkanoic acid in a small amount ratio to alkanoic anhydride. It can be used.
- a linear perfluoroalkanoic acid having 2 to 4 carbon atoms as the C2-4 perfluoroalkanoic acid.
- the content ratio of arlic anhydride and perfluoroalkanoic acid in a mixed solution obtained by dissolving the perfluoroalkanoic acid in a small amount relative to arlic anhydride Is more preferably selected in the range of 1 to 20 volumes of perfluoroalkanoic acid per 100 volumes of alkanoic anhydride.
- reaction system is kept under a dry atmosphere in which oxygen is removed in addition to moisture.
- the decomposition reaction is stopped and the reaction reagent is removed by diluting and removing the mixed solution using the polar aprotic solvent.
- the reaction product peptide is coexisted with the basic nitrogen-containing organic compound.
- a water molecule is acted on, a water treatment is performed, and then the aqueous solution impregnated in the gel carrier is converted into a polar aprotic solvent which does not cause dissolution of the gel substance and has an affinity for water.
- a mixture containing a series of reaction products obtained by the reaction for sequentially decomposing the C-terminal amino acid is used while being supported on the gel carrier.
- reaction product peptide is coexisted with the basic nitrogen-containing organic compound.
- a water molecule is acted on, a water treatment is performed, and at the same time, a reaction reagent obtained by combining the perfluoroalkanoic acid and arnic acid anhydride is inactivated and eluted from the gel.
- the gel carrier may be subjected to a re-dehydration treatment, which is an additional step of water treatment and re-dehydration treatment.
- the target peptide supported on the gel carrier is subjected to the dehydration treatment.
- a solution obtained by dissolving an alkanoic anhydride in a dipolar nonprotonic solvent that can infiltrate into the gel-like substance and can be maintained in a swollen state is used.
- the gel carrier is immersed in the mixture to cause alkanoic anhydride to act on the peptide sample of interest in the supported state, and the alkanoic anhydride is previously added to the N-terminal amino group of the peptide of interest.
- the alkanoic acid anhydride used in the pretreatment step of applying N-acylation protection to the N-terminal, and the alkanoic acid anhydride used in the step of sequentially decomposing the C-terminal amino acid, which is performed thereafter More preferably, the same alkanoic anhydride is used as the acid anhydride.
- pre-processing step of performing the N-acylation is as follows:
- the target peptide sample supported on the gel carrier is subjected to a temperature selected from a range of 30 ° C. to 80 ° C.
- a solution obtained by dissolving an alkanoic anhydride in a dipolar nonprotonic solvent that can infiltrate into the gel-like substance and can be maintained in a swollen state is used.
- the gel carrier is immersed in the sample to cause the alkanoic acid anhydride to act on the peptide sample to be carried in the supported state, and the amino group at the N-terminus of the peptide to be treated is subjected to the above-mentioned N-acylation protection by an acyl group derived from arnic acid constituting the acid anhydride,
- the gel carrier is subjected to re-dehydration treatment by diluting and removing it using a polar aprotic solvent having an affinity for the corresponding alkanoic acid. It can also be implemented.
- preparation of a peptide sample to be subjected to separation by gel electrophoresis in advance and supported on the gel carrier is performed as follows.
- FIG. 1 is a diagram showing a process flow illustrating characteristic points of an operation procedure in a process of sequentially decomposing a C-terminal amino acid from a peptide according to the present invention.
- FIG. 2 shows a reaction product obtained by sequentially decomposing the C-terminal amino acid of the globin-peptide chain of poma myoglobin according to the method of the present invention for sequentially decomposing the C-terminal amino acid from the peptide.
- FIG. 3 is a diagram showing an example of a mass spectrometry spectrum of a mixture.
- FIG. 3 shows that the C-terminal amino acid of the globin-peptide chain of poma myoglobin is sequentially degraded according to the treatment method described in Reference Example, which sequentially degrades the C-terminal amino acid from the isolated dry peptide.
- FIG. 3 is a diagram showing an example of a mass spectrometry spectrum of a reaction product mixture obtained.
- Figure 4 shows lysine residues undergoing N-acetylation in the globin 'peptide chain of ⁇ ' myoglobin, and the cleavage of the C-terminal peptide bond of arginine residues by trypsin digestion.
- FIG. 3 shows the partial amino acid sequences of 31 and 140-153.
- the method for analyzing the C-terminal amino acid sequence of a peptide according to the present invention is basically a series of peptide sequences that are obtained by sequentially decomposing and removing the C-terminal amino acid of a peptide to be analyzed, thereby shortening the peptide.
- This method employs a method of identifying the removed amino acids based on the difference between the molecular weight of this series of reaction products and the molecular weight of the original peptide. More specifically, mass spectrometry is used as a means of measuring the molecular weight of this series of reaction products and the molecular weight of the original peptide.In the process of ionization, amino acid residues constituting the peptide are used.
- a mass spectrometer that is more suitable for measurement under conditions that do not cause partial loss of atomic groups, such as MALD I—TOF—M3 (Matr 1 X Assisted Laser Desorption—onization Time—of—F It is preferable to use a light-mass spectrometer try; a matrix-assisted laser desorption / ionization time-of-flight mass spectrometer).
- the peptide sample of interest is separated by gel electrophoresis in advance, and a series of peptides is loaded on a gel carrier used in this electrophoresis. After performing the reaction operation, measure the molecular weight of a series of reaction products that are finally formed and the molecular weight of the original peptide.Free treatment from the supported gel carrier immediately before mass spectrometry. By doing this, it is possible to perform highly reproducible measurements even when the sample volume is very small. At that time, using a mass spectrometer, such as a MALD I-TOF-MS device, enables the high molecular weight resolution and accuracy of only the peptide sample portion that forms a single spot on the gel carrier.
- a mass spectrometer such as a MALD I-TOF-MS device
- the C-terminal amino acid is successively separated in the same step for a plurality of peptide samples constituting individual spots (or bands), which have been separated by gel electrophoresis in advance. After performing the digestion operation at once, the gel sections of individual spots (or bands) are separated and subjected to subsequent mass spectrometry to include them in the original sample. It is possible to perform C-terminal amino acid sequence analysis of multiple types of peptide samples with high efficiency and uniformity.
- the gel substance used is to separate individual spots (or bands) for multiple types of peptides corresponding to a specific molecular weight range.
- the conditions shown, specifically, the content ratio of polyacrylamide constituting the gel are selected to adjust the size of the gap inside the fine hole structure formed inside the gel.
- the spots (or bands) separated by the two-dimensional electrophoresis method or the SDS-PAGE method for example, have different electrophoretic velocities due to differences in peptide chain molecular weight and surface charge. Is localized.
- Such a peptide is held inside a fine pore structure formed in the gel, and does not cause the gel-like substance to dissolve when removing water impregnated in the gel-like substance, and Using a method of diluting and eluting only an aqueous solvent into the polar aprotic solvent using a polar aprotic solvent having an affinity for the peptide, the target peptide can be obtained even after the dehydration operation is completed. Can be maintained on the gel carrier at the separated spot (or band) position.
- the polar aprotic solvent used for the dehydration treatment generally has inferior affinity to a gel-like substance such as polyacrylamide constituting a gel than a water solvent, and therefore has a fine pore structure in the gel-like substance.
- a suitable polar aprotic solvent is acetonitrile (CH 3 CN) having high affinity for water, etc. Examples thereof include -tolyls having 4 or less carbon atoms, and ketones having 4 or less carbon atoms, such as acetone.
- a bipolar aprotic material whose bulk volume is reduced due to the above-mentioned dehydration treatment, and which can be infiltrated into the gel substance and can be maintained in a swollen state with respect to the contracted gel carrier, By using the solvent to re-swell, the pores of the fine hole structure are enlarged.
- a mixed solution of perfluoroalkanoic acid dissolved in a small amount in alkanoic acid anhydride in a dipolar nonprotonic solvent used for swelling of the gel by using a mixed solution of perfluoroalkanoic acid dissolved in a small amount in alkanoic acid anhydride in a dipolar nonprotonic solvent used for swelling of the gel. Then, perfluoroalkanoic acid and alkanoic anhydride are uniformly supplied to the peptide carried in the fine pore structure of the gel carrier to act.
- perfluoroalkanoic acid and the alkanoic anhydride are, for example, at the C-terminal of the peptide via the reaction mechanism described below at the following general formula (III):
- R 1 represents the side chain of the C-terminal amino acid of the peptide
- R 2 represents a side chain of an amino acid residue located immediately before the C-terminal amino acid) to form a 5-oxazolone structure.
- perfluoroalkanoic acid is used as a proton donor for the dried peptide to increase the proportion of the enol form.
- the perfluoroalkanoic acid used utilizes its proton donating ability, and the pKa of the perfluoroalkanoic acid is It is preferred to use a perfluoroalkanoic acid having a range of 0.3 to 2.5.
- Perfluoroalkanoic acids having 2 to 4 carbon atoms are more suitable, and specifically, trifluoroacetic acid (CF 3 COOH), pentafluoropropanoic acid (CF 3 CF 2 COOH), heptafluorobutanoic acid (CF 3 COOH) It is more desirable to use CF 2 CF 2 C ⁇ OH).
- the alkanoic anhydride used preferably gives an appropriate reactivity when heated to the reaction temperature. Therefore, it is preferable to use a symmetrical acid anhydride of an alkanoic acid having 2 to 4 carbon atoms. .
- a symmetrical acid anhydride of a linear alkanoic acid having 2 to 4 carbon atoms as the symmetrical acid anhydride, and particularly, a symmetrical acid anhydride of a linear alkanoic acid having 2 carbon atoms.
- the substance, that is, acetic anhydride can be suitably used. Since such an alkanoic acid anhydride is used for activating the C-terminal carboxy group, it is preferable that the alkanoic acid anhydride does not cause steric hindrance at that time. .
- the alkanoic anhydride used as the above-mentioned activating reagent is consumed according to the reaction, and therefore, is previously contained in a dipolar aprotic solvent used for swelling of the gel.
- the content ratio of alkanoic anhydride and perfluoroalkanoic acid is 100 per volume of alkanoic anhydride and 1 perfluoroalkanoic acid.
- the content of alkanoic anhydride in the dipolar nonprotonic solvent is more preferably selected in the range of 10 to 30% (vol%). desirable.
- the reaction time depends on the reaction temperature, the concentration of the alkanoic anhydride and perfluoroalkanoic acid contained in the dipolar aprotic solvent, and in addition to the dehydration treatment using a polar nonprotonic solvent. It is desirable that the appropriate selection be made in consideration of the time required for swelling of the contracted gel carrier. For example, a polyacrylamide gel (12.5% by mass) is subjected to dehydration using the above-mentioned acetate, and then immersed in a dipolar aprotic solvent such as formamide described below.
- the time required to achieve re-swelling of the gel carrier is, for example, about 3 hours at 40 ° C., so that the entire reaction time is equal to the desired amino acid after re-swelling of the gel carrier. Select the number of residues plus the time required to achieve selective degradation of the C-terminal amino acid.
- the above-mentioned dipolar aprotic solvent that causes the gel to re-swell can infiltrate into the gel-like substance and can be maintained in a swollen state, has a relatively small molecular size, and Organic solvents with good affinity are preferred.
- the enol compound has a high dipolarity that can maintain the ratio of the enol compound, and the alkanoic anhydride of the solute molecule, perfluoroalkane
- the solvent is an excellent solvent for the acid and the alkanoic acid which is a reaction by-product. It is more preferable to use a dipolar aprotic solvent which hardly volatilizes and evaporates at the above reaction temperature.For example, formamide (HCONH 2 ) and the like are necessary when polyacrylamide gel is used. They are all satisfactory.
- the reaction system is preferably kept in a dry atmosphere from which water has been removed. That is, the activated C-terminal carboxy group, which is converted into a reaction intermediate represented by the above formula (Ib) and an asymmetric acid anhydride, undergoes hydrolysis when water molecules are mixed into the reaction system. The original terminal force returns to the lipoxy group.
- the reaction system is preferably maintained in a state where water is removed.
- the amino acid present in methionine may be oxidized by oxygen mixed in the system, and the formula amount may be changed. Preventing this oxidation by oxygen is more preferable in the method of the present invention based on the measurement of the molecular weight in suppressing the strong oxidation in order to achieve higher accuracy.
- the target peptide forms an oxidized one S—S— bond with the cysteine of the p-contacting peptide, or forms a single S—S— bond in the same molecule.
- a conventional reduction treatment is performed in advance to eliminate such cross-linking, and converted to a peptide containing reduced cysteine.
- the reduced cysteine present in the peptide to be analyzed is subjected to carboxymethylation and pyridylethylation on the sulfonyl group (-SH) of the side chain. The protection is performed in advance.
- the reduced cysteine when the reduced cysteine is not protected in advance, it is oxidized by oxygen mixed in the system, and in some cases, is again oxidized —S—S— bond There is also concern that it will form.
- the target peptide is a peptide whose higher-order structure has been eliminated in advance, it is necessary to avoid the formation of an unnecessary single S—S— bond between adjacent peptides.
- the reaction system In the reaction treatment in the mixed solution using the dipolar aprotic solvent, it is more preferable that the reaction system is kept in a dry atmosphere in which oxygen is removed in addition to water.
- the atmosphere free from oxygen in a dry atmosphere.
- the reaction system is kept airtight to prevent water and oxygen from entering from outside the system, and It is also desirable that the injection and discharge operations of the gas be performed in an atmosphere of a dried inert gas, for example, nitrogen.
- a reaction represented by a reaction formula ( ⁇ ) can be performed from a 5-oxazolone ring once formed, for example:
- the reaction product obtained is an intermediate product of 5-oxazo other than those having a carboxy group at the C-terminus as shown in the above-mentioned reaction formula (II). Those that remain in the Ron ring structure, or those in which the C-terminus has become an asymmetric acid anhydride as one form of the reaction intermediate, are also mixed.
- the reaction in the successive step of selectively decomposing the C-terminal amino acid includes a process of forming a 5-oxazolone ring structure exemplified by the reaction formula (Ib) and a reaction formula ( ⁇ '). It consists of a two-step elementary reaction with the process of separating the terminal amino acid by cleavage of the 5-oxazolone ring structure exemplified in the above. Therefore, the overall reaction rate depends on both the reaction rate of each of these processes, but mainly on the concentration of the alkanoic anhydride and perfluoroalkanoic acid used, and on the reaction temperature. .
- the treatment time in the sequential step of selectively decomposing the C-terminal amino acid depends mainly on the concentrations of the alkanoic anhydride and perfluoroalkanoic acid used and the reaction temperature, and on the C to be analyzed. Considering the target amino acid length of the terminal amino acid sequence, appropriate:!: Selected.
- the sequential termination of the selective decomposition reaction of the C-terminal amino acid lowers the temperature of the reaction system and reduces the reaction reagents infiltrating into the gel carrier, i.e., perfluoroal carboxylic acid and arnic anhydride.
- the mixed solution used for the sequential decomposition reaction of the C-terminal amino acid does not cause the gel-like substance to be dissolved, and the perfluoroalkanoic acid and the alkanoic anhydride; and
- the decomposition reaction is stopped and the reaction reagent is removed by diluting and removing using a polar aprotic solvent having an affinity for the dipolar aprotic solvent.
- a dipolar aprotic solvent used for preparing a mixed solution can be used, but the 5-oxazolone ring system exemplified by the reaction formula (lb) can be used.
- perfluoroalkanoic acids and alkanoic anhydrides, as well as dipolar non-protonic solvents utilize polar non-protonic solvents that do not contribute significantly to the stability of the phenolic intermediate. It is more desirable to use a protic solvent removal step. At least in the final step of the dilution and removal of the reaction reagent, a dilution / removal operation using a polar aprotic solvent will be provided.
- polar aprotic solvents satisfying these conditions include nitriles having 4 or less carbon atoms such as acetonitrile (CH 3 CN) and 4 or less carbon atoms such as acetone. And the like ketones.
- a carboxy group is not expressed at the C-terminus, which is generated in the sequential step of selectively decomposing the C-terminal amino acid and is exemplified in the above reaction formula (II).
- a reaction intermediate may be provided with an additional hydrolysis treatment for the purpose of reverting to a form in which a carboxy group is exposed at the C-terminus.
- the reaction product peptide is coexisted with the basic nitrogen-containing organic compound.
- Water molecules are acted on, water is applied, and then the aqueous solution impregnated in the gel carrier is caused to dissolve the gel-like substance.
- a polar aprotic solvent having an affinity for water. It is preferable to provide a re-dehydration step.
- the reaction product has a form in which a carboxy group is exposed at the C-terminus, and this form gives a major peak when subsequently analyzed by mass spectrometry.
- identification of a peak indicating a molecular weight corresponding to a series of reaction products can be more easily performed.
- the basic nitrogen-containing aromatic ring compound or tertiary amine compound is converted into a 5-oxazolone ring structure represented by the reaction formula ( ⁇ ) and a reaction intermediate (acid anhydride) in the next stage.
- a reaction intermediate (acid anhydride)
- it catalyzes the hydrolysis reaction o, it does not itself react with the 5-oxazolone ring structure or a reaction intermediate (acid-free Y water OC substance) to produce unnecessary by-products, and as a suitable base catalyst Function.
- the polar aprotic solvent used in the re-dehydration step is preferably one having high solubility even for a basic nitrogen-containing aromatic ring compound or a tertiary amine compound.
- polar aprotic solvents for the redehydration step satisfying these conditions include nitriles having 4 or less carbon atoms such as acetonitrile (CH 3 CN). Examples thereof include ketones having 4 or less carbon atoms, such as acetone.
- the basic nitrogen-containing aromatic ring compound or tertiary amine compound used in the above-mentioned hydrolysis treatment reacts, for example, with the remaining C-terminal having reached an asymmetric acid anhydride to form an amide bond. This is preferable because it does not form and when formed into an aqueous solution, a uniform solution can be obtained.
- a monocyclic nitrogen-containing aromatic ring compound having high solubility in a polar aprotic solvent is preferable.
- pyridine can be more preferably used.
- the tertiary amine compound that can be used preferably has a basicity similar to the relatively weak basicity of the pyridine base.
- DMA E (2- (dimethylamino) ethanol: (CH 3 ) 2 N—CH 2 CH 2 OH)
- DMA E 2, 3- (dimethylamino) ethanol: (CH 3 ) 2 N—CH 2 CH 2 OH
- pyridine it is preferable to select pyridine in the range of 5 to 15% by volume, more specifically, 10% by volume, based on the total volume of the aqueous solution.
- DMAE it is preferable to select DMAE in the range of 1 to 20% by volume, more specifically, 10% by volume, based on the total volume of the aqueous solution.
- the above-mentioned hydrolysis treatment involves, after the sequential decomposition reaction of the C-terminal amino acid, once diluting the reaction reagents arnic anhydride and perfluoroalkanoic acid using a polar aprotic solvent. Not only after the removal operation has been completed, but also the sequential decomposition reaction of the C-terminal amino acid and the hydrolysis treatment can be performed continuously. Specifically, the sequential decomposition reaction of the C-terminal amino acid is carried out by lowering the reaction temperature and stopping the reaction while adding an aqueous solution containing an organic base.
- the reaction reagent which is a combination of acids, is deactivated and eluted from the gel, stopping the sequential decomposition reaction of the C-terminal amino acid and removing the inactive reagent. Subsequently, the reaction product can be subjected to a hydrolysis treatment.Finally, by performing a re-dehydration treatment step using a polar aprotic solvent, it is possible to cope with the alkanoic anhydride together with the aqueous solution containing the organic base. Since alkanoic acid, perfluoroalkanoic acid, and dipolar aprotic solvent are removed and dehydration is performed, once the washing / removal operation using a polar aprotic solvent is once provided in the middle, There will be no difference.
- the process of using a mixed solution obtained by adding a small amount of perfluoroalkanoic acid to the above-mentioned alkanoic anhydride is used.
- a pretreatment step in which the N-terminal amino group of the peptide of interest is protected in advance by N-acylation protection with an acyl group derived from the arnic acid constituting the alkanoic anhydride.
- a reaction intermediate is formed in which the C-terminal force of the peptide is activated. It is inferred. If this reaction intermediate reacts with the N-terminal amino group of the adjacent peptide to form an amide bond, a shortened reaction product of the target peptide cannot be obtained.
- the reaction for producing such a reaction intermediate occurs with respect to the peptide carried in the pore structure in the gel-like substance, the accidental secondary reaction generated between a plurality of peptide reaction intermediates occurs. Although the frequency of the reaction is not high, it is more desirable to apply N-acylation protection in advance.
- the alkanoic anhydride reacts with the amino group at the N-terminal of the peptide. Since N-acylation usually occurs, N-acylation protection is performed in the system, but it is more preferable to perform pretreatment for N-acylation protection in advance.
- the pretreatment step of protecting the N-terminal amino group with N-acylsig is a reaction utilizing alkanoic anhydride
- the alkanoic anhydride is dissolved in a dipolar aprotic solvent similar to the solvent used for preparing a mixed solution obtained by adding a small amount of perfluoroalnic acid to the alkanoic anhydride, and then dissolved. By immersing the dehydrated gel carrier in the solution, the gel carrier swells and infiltrates into the gel-like substance.
- the intramolecular polarization of alkanoic anhydride is induced and acts on the amino group of the peptide as an electrophilic reagent.
- the reaction proceeds.
- a reaction temperature of 50 ° C or higher, but in general, such a reaction is performed in a closed reaction vessel, so that the mechanical strength in the reaction vessel is increased. In consideration of this, it is desirable to select the temperature within the range of 100 ° C. or less.
- Alkanic acid is produced in association with the N-acylation reaction, but in a small amount. Secondary protons due to the proton-donating ability of the strong alkanoic acid and the coexisting alkanoic anhydride are produced.
- the reaction is usually not a problem in the above temperature range. More specifically, the alkanoic acid generated in the system has, for example, a much lower acid catalysis and a smaller abundance than perfluoroalkanoic acid.
- the main reaction in the step of sequentially decomposing C-terminal amino acids using perfluoroalkanoic acid and carboxylic anhydride is described in In this case, the reaction for forming the 5-oxazolone ring structure does not occur until a secondary reaction occurs.
- the O-acylation reaction proceeds at the serine residue present in the peptide and also at the hydroxy group of the threonine residue side chain, thereby protecting the peptide.
- the phenolic hydroxy group of the side chain of the tyrosine residue present in the peptide is partially diacylated, though the reactivity is different.
- the amino group on the side chain of lysine residue, and the hydroxy group on the side chain of threonine residue in the case of serine residue are all protected and modified. And no longer participate in unnecessary side reactions. From this viewpoint as well, it is usually preferable to carry out a pretreatment step of N-acylation protection of the amino group at the N-terminus of the peptide.
- threonine residues one NH—CH (CH (CH 3 ) OH) -CO-
- a hydroxy group ( ⁇ ) is present at the 3-position.
- hydrolysis proceeds by the mechanism described above, and cleavage of the peptide occurs at the N-terminal side of the threonine residue.
- reaction products derived from these side reactions coexist, in some cases, they may be a factor that hinders the measurement of the target reaction product during mass spectrometry.
- a branched peptide in which the N-terminal partial peptide is linked to the hydroxyl group (1 OH) at position 3] will have an amide bond at that site.
- the oxazolone ring structure is not formed, and the selective decomposition of the C-terminal amino acid does not proceed further.
- a dehydration step is provided in advance to remove water impregnated in the gel, and then select a condition under which water is not mixed into the reaction system.
- secondary reactions such as cleavage of the peptide chain at the specific amino acid residue or branching of the peptide chain described above occur. The reaction is suppressed.
- N-acylation protection and O-acylation protection reactions by alkanoic anhydride present at a much higher concentration than perfluoroalkanoic acid proceed simultaneously, resulting in peptide chain cleavage or peptide cleavage. Secondary reactions such as chain branching are further suppressed and avoided.
- the N-terminal amino group of the peptide was added to the peptide side chain in addition to N-acylich protection.
- the side chain reaction such as cleavage of the peptide chain or branching of the peptide chain during the selective decomposition process of the C-terminal amino acid is more reliably suppressed. Avoidance can be performed.
- the content of the alkanoic anhydride in the solution for dissolving the alkanoic anhydride in the dipolar nonprotonic solvent used in this pretreatment step achieves the desired reactivity according to the reaction temperature.
- the concentration of the alkanoic anhydride in the tonic solvent in the range of 10 to 30% by volume, for example, about 10% by volume.
- the reaction temperature is in the range of 30 ° C. to 80 ° C., preferably in the range of 50 ° C. to 80 ° C., more preferably It is preferable to select such a reaction temperature around room temperature or within a range slightly higher than room temperature. More specifically,
- the reaction time depends on the reaction temperature, the concentration of the alkanoic anhydride contained in the dipolar aprotic solvent, and the gel carrier that shrinks due to the dehydration treatment using the polar aprotic solvent. It is desirable to select an appropriate value in consideration of the time required for swelling.
- the solution dissolving the used arnic acid anhydride in the dipolar aprotic solvent is removed, and the polar non-protonic solvent used in the above-mentioned dehydration treatment step is further removed. It is desirable to dilute and remove the alkanoic anhydride, the dipolar aprotic solvent, and the alkanoic acid formed, which are impregnated in the gel. That is, when the alkanoic anhydride solution impregnated in the gel remains, the peralkanoic acid is then added to the alkanoic anhydride to be used in the step of selectively decomposing the C-terminal amino acid.
- the perfluoroalkanoic acid does not rapidly enter the inside of the gel.
- the polar aprotic solvent used in the dehydration step is used to remove the alkanoic anhydride solution impregnated in the gel. It is desirable to dilute and remove.
- the operation of terminating the reaction and removing the reaction reagent is performed by lowering the temperature instead of diluting and washing with a polar aprotic solvent and reducing the temperature of the decomposition reaction.
- water is added to inactivate the alkanoic anhydride in the reaction reagent and elute the alkanoic anhydride and the corresponding alkanoic acid in the gel, thereby terminating the reaction and removing the reaction reagent
- the water in which the gel carrier is immersed is diluted and removed using the polar aprotic solvent used in the above-described dewatering process. It is necessary to perform a dehydration treatment. That is, if water remains in the gel carrier,
- the method for selectively decomposing a C-terminal amino acid according to the present invention can be carried out in a form including all of a dehydration step, a pretreatment step, a step of selectively decomposing a C-terminal amino acid, and a post-treatment step. It is more preferable.
- the reagents used in that step are removed from the gel to stop each reaction. Therefore, as described above, a dilution / washing operation using a polar aprotic solvent similar to the polar aprotic solvent used in the dehydration treatment step is provided.
- the gel carrier can be temporarily stored in a state of being immersed in the polar aprotic solvent during the next step.
- the gel carrier can be temporarily stored after the polar aprotic solvent is evaporated and removed to make it dry.
- the molecular weight of a series of reaction products prepared by the sequential removal of the C-terminal amino acid and the molecular weight of the original peptide are determined by mass spectrometry. It is determined by using the measurement results obtained by the method, and the amino acids corresponding to the difference in the molecular weight are specified. Therefore, it is usually desirable that the original peptide remains in the mixture subjected to the measurement by the mass spectrometry so that its molecular weight can be specified.
- the method for analyzing the C-terminal amino acid sequence of a peptide according to the present invention is applied to the analysis of a C-terminal amino acid sequence up to about 10 amino acids in length. It is desirable that the content ratio of a series of 10 or more reaction products be the one with the minimum content ratio but the maximum content ratio, but at least not less than about 10: 1. It is also desirable that the residual amount of the original peptide does not fall below lZi0 at least with respect to the reaction product with the maximum content ratio. Good.
- the required C-terminal amino acid sequence information is often within 10 amino acids, and if the treatment time is selected to such an extent that decomposition of about 10 amino acids proceeds, it is possible to satisfy the condition regarding the content ratio of the above. .
- mass spectrometry is used to measure the molecular weight, but during the ionization process, fragmentation is partially generated from amino acid residues that make up the peptide, and ionization is performed under conditions that suppress fragmentation. Measurement using a mass spectrometer equipped with means is more suitable. Further, peptides and the like have a high molecular weight, and it is preferable to use a mass spectrometer suitable for measurement of such a high molecular weight, for example, a MALDI_TOF-MS device.
- a peptide sample to be analyzed is subjected to a series of treatments in a state in which the peptide sample to be analyzed is separated by gel electrophoresis in advance and is supported on a gel carrier.
- the treated reaction product is selectively released and recovered from the spot on the gel, and subjected to mass spectrometry. At that time, the corresponding cation and anion species are removed. It is preferable to use a MA LDI-TOF-MS device that can measure both.
- the maximum measurable amino acid length of the peptide must not exceed 20 to 30 amino acids. Is desirable.
- the corresponding amino acid is identified based on the difference in molecular weight, it is possible to distinguish between amino acid residues having a difference in formula weight of 1, such as Asn and Asp, and Gln and Glu, with high accuracy.
- the molecular weight of the longest peptide serving as a reference i.e., the peptide from which the C-terminal amino acid has not been removed, does not exceed 300, more preferably does not exceed 200,000. Is more preferable.
- the length be at most 30 amino acids, more preferably not more than 20 amino acids.
- specificity of a cleaved amino acid sequence site Specific cleavage of the peptide is carried out using a protease having Of the amino acid length range.
- the method for analyzing the C-terminal amino acid sequence of peptides according to the present invention can be applied. That is, in the present invention, although the peptide can be eluted from the gel carrier by performing a specific fragmentation treatment, the reaction product obtained by sequentially decomposing the C-terminal amino acid is placed on the gel carrier.
- the main object is one that maintains the state of being carried, specifically, one in which the number of amino acid residues in the original peptide chain is at least 50 amino acids or more, and usually 100 amino acids or more.
- the specific cleavage of the peptide using a protease having the specificity of the cleaved amino acid sequence site is usually carried out after the above-mentioned post-treatment step of performing the hydrolysis treatment. Specifically, after completion of the post-treatment step, a diluting / washing operation using a polar aprotic solvent, and a re-dehydration treatment are performed, and the peptide supported on the gel carrier is renewed. An aqueous solution containing the protease is allowed to act on the chain.
- the peptide chain carried on the gel carrier is cut into a plurality of peptide fragments as a result of cleavage at the specific cleavage amino acid sequence site by the action of a protease that penetrates into the hole structure in the gel.
- proteases that can be used for peptide fragmentation by proteases on this gel carrier include trypsin, which cleaves the C-terminal peptide bond of lysinanoleginin residue, and C-terminal peptide bond of glutamic acid residue. It is possible to use commonly used proteases for processing peptide fragmentation, such as the V8 enzyme that cleaves.
- the specific cleavage treatment of the peptide is performed by digestion of a protease having the specificity of the cleavage amino acid sequence site, for example, chemical cleavage such as CNB r having a specificity of cleavage of the methionine residue at the C-terminal amide bond. It is also possible to use a cleavage method that uses an appropriate reagent. Such a protease digestion or a chemical cleavage method is applied to obtain a C-terminal peptide fragment obtained from a long amino acid-length peptide chain in a desired amino acid length range.
- the number of cleavage sites in chemical cleavage is, for example, about 10 to 2, preferably about 7 to 3, per 100 amino acids. If the cleavage site is present at the above frequency, the average amino acid length of the obtained peptide fragment can be 10 to 50 amino acids, preferably 15 to 35 amino acids, and accordingly, the C-terminal side Peptide fragments can also be in the amino acid length ranges described above. That is, for example, in the molecular weight measurement using a MA LDI-TOF-MS device, a C-terminal peptide fragment having a suitable molecular weight range can be prepared.
- the peptide chain carried on the gel carrier is retained in the pore structure in the gel due to its long amino acid length, but the peptide fragmentation treatment shortens the amino acid length.
- the peptide fragments are easily released from the gel carrier and elute, for example, in a protease solution. With this fragmentation treatment, peptide fragments eluted from the gel carrier are recovered. Next, for example, desalting treatment is performed to separate from the components contained in the buffer solution, and the crude peptide fragments are dried and recovered.
- a long peptide such as a protein constituting a three-dimensional structure
- one SS—S— bond is formed between cysteine residues in a long peptide due to protein folding.
- the C-terminal portion of the peptide is in a state where it does not constitute a secondary structure, for example, after being subjected to a deforming treatment, the peptide sample is subjected to the second step. It is desirable to separate a single spot on a gel carrier by gel electrophoresis such as two-dimensional electrophoresis or SDS-PAGE.
- the defolding state is applied, for example, to complete a series of chemical processing steps, and to perform specific fragmentation processing of the peptide using the above-mentioned protease before mass spectrometry.
- there is an advantage that the separation of the obtained C-terminal peptide fragment is generally easy even when it is necessary to carry out the reaction.
- the method for analyzing the C-terminal amino acid sequence of a peptide according to the present invention includes not only determining the C-terminal amino acid sequence of a linear peptide, but also, for example, determining the amino acid sequence of a cyclic peptide. It can be opened in advance, converted into a linear peptide, and applied to its C-terminal amino acid sequencing. More specifically, various microorganisms and the like produce a cyclic peptide-type compound having a biological activity, and can be used for determining the partial amino acid sequence thereof. Furthermore, some proteins have a form in which a plurality of peptide chains form a single SS bond between cysteine residues between the chains.
- This single S—S— bond is reduced, cross-links between cysteine residues are eliminated, individual peptide chains are separated into individual spots by gel electrophoresis, and the C-terminal amino acid sequence is analyzed.
- the peptide sample of interest is converted into a linear peptide, which is subjected to separation by gel electrophoresis in advance to obtain a single spot supported on the gel carrier.
- the gel electrophoresis method is not limited to the conventional SDS-PAGE method in which electrophoresis is performed in one-dimensional direction, but also performs two-dimensional electrophoresis on a gel to achieve higher separation. The law may be applied. Suitable for such two-dimensional electrophoresis Even if the peptide sample to be separated is free from contaminants and has a smaller sample volume, the C-terminal amino acid sequence analysis method of the present invention allows the C-terminal amino acid sequence analysis to be performed. It becomes possible.
- the target peptide that forms a single S—S— bond between cysteine residues in the molecule is 2-sulfanylethanol (HS—C 2 H 4 - OH: 2-mercaptoethanol), DTT (dithiothreitol: threo one 1, 4-Jisurufa two Lou 2, 3-heptane diol) by adding a reducing reagent, such as, electrophoresis under reducing conditions It is preferable to perform single spotting.
- a single S—S— bond between cysteine residues in the molecule is reduced in advance, and a modification of reduced cysteine, such as carboxymethylation using eodoacetic acid, is performed. It is preferable to perform single spotting.
- the C-terminal fragment derived from a series of reaction products obtained by sequentially decomposing C-terminal amino acids by the peptide fragmentation treatment with a protease on the gel carrier described above By measuring the molecular weight of fragments derived from the middle part of the peptide chain and the N-terminal side, the fragments present in the original peptide chain In the amino acid sequence of the entire peptide chain as the origin, such as the interval between the locations of the cleavage amino acid sequence sites specific to the protease and the presence of the specific cleavage amino acid sequence site at the N-terminal of the C-terminal fragment.
- the N-alkanoyl for the N-terminal amino group is used.
- N-alkanoylation of the lysine residue one NH—CH (CH 2 CH 2 CH 2 CH 2 NH 2 ) -CO-) to the ⁇ -position amino group, and simultaneously, the serine residue (one NH—CH ( CH 2 ⁇ H) -CO-) ⁇ Threonine residue (one NH-CH (CH (CH 3 ) OH) -CO-) O-alkanoylation of the hydroxyl group, tyrosine residue (one NH—CH
- the neutralization of (CH 2 -C 6 H 4 -OH) 1 C 0-) to a phenolic hydroxy group is carried out.
- the ester bond to the alcohol-type hydroxy group is more rapidly formed as compared with the ester bond to the phenol-type hydroxy group, accompanying the hydrolysis treatment in the presence of the organic nitrogen base. Hydrolysis is performed.
- the N-alkanoylation of the N-terminal amino group and the lysine residue one NH—CH (CH 2 CH 2 CH 2 CH 2 NH 2 ) -CO-
- N-Al force to the amino group at the ⁇ -position and in some cases, tyrosine residue (one NH—CH (CH 2 -C 6 H 4 Only the alkanolization of -OH) -CO-) to the phenolic hydroxy group will remain.
- the molecular weight difference between the multi-acetylated product and the deacetylated product is high.
- the molecular weight difference between the multi-acetylated product and the deacetylated product is high.
- an integral multiple of the formula weight 42, specifically, 84, 126, 168 is a formula weight of the serine residue (—NH—CH (CH 2 OH) —CO—) 87, Glutamine residue (one NH—CH (CH 2 CH 2 -CONH 2 ) —CO—) Formula 1 28, Glutamic acid residue (one NH—CH (CH 2 CH 2 -COOH) -CO-) Formula weight of 129, similar to the formula weight of N-acetyl-lysine residue (_NH—CH (CH 2 CH 2 CH 2 CH 2 NH—COCH 3 ) -CO-) 1 70, and in some cases multi-acetylation There is a concern that the body which is misidentified as a main peak and which has been deacety
- heme protein consisting of 153 amino acids, and myoglobin derived from poma, were obtained by analyzing the C-terminal amino acids of the protein partial globin and peptide chains. Analysis of the acid sequence was performed.
- the amino acid sequence possessed by the gamma myoglobin globin peptide chain used as the analysis sample used in the present example has already been determined, and the accuracy of the C-terminal amino acid sequence identification by the analysis method according to the present invention has been known. Verified.
- a peptide solution containing only a globin peptide chain portion at a concentration of 0.2 ⁇ g Z i L is prepared for a commercially available puma myoglobin sample.
- the antioxidant treatment is performed in advance by adding a reducing reagent such as DTT or DTT.
- This peptide solution is spotted on a polyacrylamide gel with a gel concentration of 12.5% by mass. After electrophoresis, the band of the desired globin 'peptide chain is identified by Coomassie' staining. In this example, the gel of the strong stained band is cut out, and the gel slice is subjected to the following series of operations.
- the gel slice is placed in an airtight tube, 1 ml of acetonitrile is poured, and the mixture is stirred for 15 minutes. Thereafter, the acetoetrile is discarded, and acetonitrile lm1 is newly added, and the mixture is further stirred for 15 minutes. Extraction of water impregnated in the gel using this acetonitrile is performed three times in total, and the gel is dehydrated. The gel volume shrinks during the dehydration treatment.
- the gel which has initially shrunk in volume, re-swells and returns to its original volume according to the infiltration of the solvent formamide.
- the solute acetic anhydride acts on the globin 'peptide chain carried in the re-swollen gel at the above-mentioned heating temperature.
- a selective acetylation reaction proceeds to the N-terminal amino group of the peptide.
- the formamide solution of acetic anhydride is removed and placed in a tube container. Inject 1 ml of acetonitrile and stir for 15 minutes. Thereafter, the aceto-tolyl was discarded, 1 ml of acetonitrile was newly added, and the mixture was further stirred for 15 minutes. Extraction of the formamide solution impregnated in the gel using this acetonitrile is performed three times in total, and the solvent removal (formamide) treatment in the re-swelled gel is performed. The gel volume shrinks due to the solvent removal treatment, and at the same time, the gel is dehydrated. .
- heptafluorobutanoic acid (HFBA: C 3 F 7) was placed in the tube containing the gel slice in a state in which the obtained globin / peptide chain decorated / protected by the acetyl group was supported in the gel.
- COOH 1 volume 0/0
- injecting formamide 1 ml of acetic anhydride 10 volume 0/0.
- the temperature of the whole container is heated to 40 ° C. while stirring the stoppered container, and the temperature is maintained at that temperature for 16 hours.
- the gel which has initially shrunk in volume, re-swells and returns to its original volume according to the infiltration of the solvent formamide.
- HFBA and acetic anhydride By causing HFBA and acetic anhydride to act on the C-terminal of the peptide chain carried in the re-swelled gel at the above-mentioned heating temperature, the selective decomposition reaction of the C-terminal amino acid of the peptide chain proceeds.
- keto-enol tautomerized isomerization represented by, and acetic anhydride acts on the C-terminal carbonyl group.
- DMAE ((CH 3 ) 2 N-CH 2 CH 2 OH) 1 m 1 of a 10% by volume aqueous solution was placed in the container containing the gel slice in which the mixture containing the reaction product was supported. Inject. While stirring the stoppered container, the temperature of the entire container is heated to 60 ° C. and maintained at that temperature for 1 hour. At this time, the gel that has been dehydrated rapidly re-swells and returns to its original volume as the solvent water infiltrates. By causing water molecules to act on the peptide chains and reaction products carried in the re-swelled gel in the presence of the basic nitrogen-containing organic compound at the above-mentioned heating temperature, the water treatment proceeds.
- the hydrolysis treatment in this post-treatment is mainly that in the mixture, the C-terminus of the reaction product peptide remains in a 5-oxazolone structure other than the one converted to a carboxy group, or an asymmetric acid anhydride Since the product that has progressed to the conversion into a product is also in the form of a contained mixture, it is subjected to a hydrolysis treatment to convert the C-terminus of the peptide into a carboxy group.
- a serine residue one NH—CH (CH 2 ⁇ H) —CO 2 -
- Yato threonine residues one NH- CH (CH (CH 3) OH) O- against hydro alkoxy groups present -CO-
- Asechirui spoon protected is hydrolyzed, deprotected is made, also, Chi port Shin residue partially proceeds to the hydrolysis of O- Asechiruihi protection to phenolic hydroxyl groups of (an NH- CH (CH 2 -C 6 H 4 -OH) -CO-).
- N-terminal amino group with higher selectivity has a higher selectivity.
- the aqueous solution remaining in the container is removed, 1 ml of acetoethrile is poured into the container, and the mixture is stirred for 15 minutes. Thereafter, the acetonitrile is discarded, 1 ml of acetonitrile is newly added, and the mixture is further stirred for 15 minutes. Extract the aqueous solution impregnated in the gel using this acetonitrile three times in total, and perform the dehydration treatment in the re-swelled gel. Gel volume shrinks during dehydration.
- globin-peptide chain of ⁇ ma 'myoglobin is composed of 153 amino acids, it deviates from the appropriate molecular weight range in mass spectrometry, and is subjected to tryptic digestion peptide fragmentation.
- a trypsin-containing aqueous solution is added to a container in which the above-mentioned post-treated and dehydrated gel slices are placed, and the fragment of the peptide chain is kept in a state of being supported on the gel carrier. Perform the conversion.
- the aqueous solution containing trypsin was prepared by adding trypsin to 0.067 ⁇ m in ammonium bicarbonate buffer solution (pH 8). It is contained at a concentration of L. Tryptic digestion is performed at 37 ° C for 4 hours with stirring and enzymatic reaction. At that time, the gel that has been dehydrated rapidly re-swells and returns to its original volume as the solvent water infiltrates. By causing the trypsin infiltrating into the gel to act on the peptide chain and the reaction product carried in the re-swelled gel together with the buffer at the heating temperature, enzymatic digestion specific to trypsin is performed. proceed.
- the peptide chain and the reaction product can also be deprotected in the above-mentioned post-treatment step to N-acetylation of the N-terminal amino group and lysine residue (one NH—CH (CH 2 CH 2 CH 2 CH 2 NH 2 ) —CO—) to the N-acetylated amino group at the ⁇ -position is maintained, and the N-acetylated lysine residue may be digested by trypsin digestion. The cleavage of the c-terminal peptide bond is not performed, but only the cleavage of the C-terminal peptide bond of the algyun residue proceeds.
- the amino acid sequence possessed by the globin-peptide chain of the pima 'myoglobin has already been determined, and the original peptide chain consisting of 153-amino acids shown in FIG.
- the fragments containing the partial amino acid sequences of 9, 140-153 are subjected to trypsin digestion. Therefore, a series of reaction products generated by the above-described sequential decomposition treatment of the C-terminal amino acid include each C-terminal amino acid together with the C-terminal fragment containing the partial amino acid sequence of 140-153 amino acid.
- the fragmented peptides eluted from the gel into the trypsin solution in the container are recovered. After subjecting the solution containing the recovered peptide fragment mixture to desalting treatment, perform freeze-vacuum drying treatment.
- reaction products after peptide fragmentation by post-treatment and trypsin digestion The reaction products after post-treatment and peptide fragmentation and the C-terminal fragment of globin 'peptide chain obtained by performing the above series of treatments for the mixture, the molecular weight of each contained peptide fragment is measured by mass spectrometry.
- a mass spectrometer specifically, a MALDI-TOF-MS device was used for the peptide fragment mixture sample that had been subjected to the above-mentioned drying treatment, and the main ion reflecting the molecular weight of each peptide fragment was used. Measure and compare the species peak mass and its relative signal strength.
- so-called "negative 'mode" measurement in which negatively charged ion species are guided to a detector, is employed for separation of ion species.
- FIG. 2 shows a mass spectrometry spectrum measured for a mixture containing a tryptic digested fragment of the reaction product that has been subjected to the sequential decomposition treatment of the C-terminal amino acid in the above-described series of treatment methods in this example.
- Table 1 shows the mass values of the measured peaks and the original globin It shows the difference from the mass value of the peak due to the C-terminal fragment of the peptide chain, and the amino acids removed from each reaction product fragment and the morphology of each reaction product specified therefrom.
- the partial amino acid sequence of the C-terminal fragment consisting of 140 to 153 amino acids is N-acetylated on two lysine side chains, NDI AAK (Ac) YK (Ac ) It is ELGFQG, and the series of peaks shown in Fig. 1 is confirmed to correspond to the sequential degradation of two amino acids, glycine and glutamine, from the C-terminus. That is, it is verified that the peptide chain separated as a band on the above-mentioned gel slice to be analyzed is actually a globin ′ peptide chain.
- a peptide solution containing only a globin-peptide chain portion at a concentration of 1.0 ⁇ g ZL prepared from a commercially available puma myoglobin sample. Transfer the peptide solution into a test tube and freeze-dry to prepare a dry peptide powder sample. (Pre-processing operation)
- the vial containing the dried peptide sample was placed in a glass-sealed reaction vessel of a stoppered airtight test tube type equipped with a port for evacuation sealed with a Teflon cock-valve.
- a predetermined amount of the following liquid reagent is separately placed in a reaction vessel.
- acetic anhydride 300 wL to which 5% by volume of acetic acid was added was used.
- the vial containing the dried peptide sample was placed in the glass reaction vessel, and then the reaction vessel was cooled. Is evacuated and hermetically sealed.
- the whole of the hermetically sealed reaction vessel is kept at 50 ° C for 2 hours, and vaporized acetic anhydride and acetic acid supplied from the liquid reagent in the vessel are allowed to act on the dried peptide sample.
- acetic anhydride as the acylating reagent in the presence of acetic acid on a dried peptide sample, an acetyl / Reich reaction selective for the N-terminal amino group of the peptide proceeds.
- N-acetylation of the lysine residue one NH—CH (CH 2 CH 2 CH 2 CH 2 NH 2 ) —CO—
- Serine residue (1-NH—CH (CH 2 OH) -CO-) ⁇ Preferable acetylation of hydroxy group present in threonine residue
- (1-NH—CH (CH (CH 3 ) OH) -CO-) O-acetylation of a tyrosine residue (—NH—CH (CH 2 —C 6 H 4 —OH) —CO—) to a phenolic hydroxy group is performed.
- the obtained vial holding the globin / peptide chain modified / protected by the acetyl group was placed in an airtight test tube-type glass reaction vessel with a stopper, and the glass reaction was performed. Separately, add prescribed amounts of the following liquid reagents into the container.
- the whole of the hermetically sealed reaction vessel is kept at 40 ° C. for 3 hours, and acetic anhydride and HFBA supplied from the liquid reagent in the vessel are allowed to act on the dried peptide sample. Meanwhile, HFBA and acetic anhydride are allowed to act on the C-terminal of the peptide chain at the above-mentioned heating temperature.
- the sequential decomposition reaction of the amino acid at the C-terminal of the peptide chain proceeds. After the selective decomposition treatment of the C-terminal amino acid is completed, unreacted acetic anhydride, HFBA, etc. remaining in the reaction vessel are distilled off under reduced pressure, and the remaining acetylation protection / modified globin Drying of the mixture of the peptide chain and the resulting reaction product.
- the vial holding the dried sample of the mixture containing the reaction product was attached to the same glass-sealed test tube-shaped reaction vessel with a stopper, and separately placed in the glass reaction vessel. A predetermined amount of the following liquid reagent is added.
- This post-treatment is mainly carried out in the above-mentioned mixture, except that the C-terminus of the reaction product peptide remains in a 5-oxazolone structure other than that converted into a carboxy group, or is an asymmetric acid anhydride. Since the mixture that has progressed to the conversion into a mixed state is still contained, it is subjected to a hydrolysis treatment to convert the C-terminal of the peptide into a carboxy group. That is, as a liquid reagent for post-treatment, an aqueous solution (300 iL) in which 10% by volume of DMAE was dissolved was used, and a vial containing a dry sample was stored in the glass reaction vessel. Under cooling, the inside of the reaction vessel is evacuated and sealed in an airtight state.
- the whole hermetically sealed reaction vessel is heated at 60 ° C. for 1 hour, and vapor DMAE and water molecules supplied from the liquid reagent in the vessel are allowed to act on the dried sample.
- the asymmetric acid anhydride and 5-oxazolone structure are formed in the presence of the organic base, DMA E, By the action of water molecules, water is added and converted into a form having a carboxy group at the C-terminus.
- the globin 'peptide chain of' myoglobin ' is composed of 153 amino acids, it deviates from an appropriate molecular weight range in mass spectrometry, and is subjected to peptide fragmentation by trypsin digestion.
- a sample obtained by drying the mixture of the post-treated reaction product is placed in a container, an aqueous solution containing trypsin is added, and fragmentation of the peptide chain is performed.
- the aqueous solution containing trypsin contains trypsin at a concentration of 0.1 ⁇ g / ⁇ L in 3-pyridine acetate buffer (pH 7), and the trypsin digest is stirred at 37 ° C. While performing the enzyme reaction for 8 hours.
- reaction solution After trypsin digestion, the reaction solution is subjected to desalting treatment using Zip Tip, separation and recovery of peptide fragments, and then vacuum drying of these peptide fragments.
- reaction product after peptide fragmentation by post-treatment and trypsin digestion The reaction product after post-treatment and peptide fragmentation and the C-terminal fragment of globin 'peptide chain obtained by performing the above series of treatments
- the molecular weight of each contained peptide fragment is measured by mass spectrometry.
- the mass of the main ion species peak which reflects the molecular weight of each peptide fragment, was measured using a mass spectrometer, specifically, a MALD I-TOF-MS device, for the dried peptide fragment mixture sample. And the relative signal strength is measured and compared.
- a MALD I-TOF-MS device so-called negative mode measurement, in which a negatively charged ion species is guided to a detector, is employed for the separation of ion species.
- Figure 3 shows the mass spectrometry spectrum measured for the mixture containing the tryptic digested fragments of the reaction products that had been subjected to the sequential degradation of the C-terminal amino acid in the series of treatments described in this reference example.
- Table 2 shows the measured mass of the peak, the difference from the mass of the peak due to the C-terminal fragment of the original globin / peptide chain, and the amino acids removed from each reaction product fragment identified therefrom.
- each reaction Indicates the form of the product.
- the method for analyzing the C-terminal amino acid sequence of a peptide comprises the steps of sequentially decomposing and removing the C-terminal amino acid of the peptide; After separation by electrophoresis, the gel carrier dehydrated using a polar aprotic solvent while being supported on the gel carrier, and the gel carrier shrunk by the dehydration process is removed.
- the perfluoroalkanoic acid is dissolved in a dipolar aprotic solvent in a small ratio to the alkanoic anhydride in a dipolar aprotic solvent that can infiltrate into the gel-like substance and maintain the swelling state.
- the gel carrier is re-swelled at a temperature selected in the range of 30 ° C to 80 ° C by immersion in a mixed solution containing
- a series of reaction products are prepared by reacting alkanoic anhydride with perfluoroalkanoic acid, passing through the 5-oxazolone structure, and decomposing the C-terminal amino acid with cleavage of the 5-oxazolone ring.
- the control and controllability of the maximum amino acid length of the shortened C-terminal amino acid sequence, which is achieved in a series of obtained reaction products, is improved. it can. Therefore, in addition to the excellent controllability in sequentially decomposing and removing the C-terminal amino acid of this peptide, and the advantages of mild reaction conditions, for example, the permissible range of variation in the reaction temperature, After performing separation by gel electrophoresis in advance, analysis is performed while the gel is supported on the gel carrier.Therefore, the complicated steps of separating and recovering from the gel carrier are omitted, and The method has the practical advantage that sample loss due to low yield can be avoided, and the method for analyzing the C-terminal amino acid sequence of a peptide according to the present invention is a more versatile analysis method.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03775962A EP1574860A4 (en) | 2002-11-29 | 2003-11-28 | PROCESS FOR ANALYZING A C-TERMINAL AMINO ACID SEQUENCE OF A PEPTIDE |
US10/536,824 US7670841B2 (en) | 2002-11-29 | 2003-11-28 | Method of analyzing C-terminal amino acid sequence of peptide |
AU2003284493A AU2003284493A1 (en) | 2002-11-29 | 2003-11-28 | Method of analyzing c-terminal amino acid sequence of peptide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-347777 | 2002-11-29 | ||
JP2002347777A JP4257492B2 (ja) | 2002-11-29 | 2002-11-29 | ペプチドのc末端アミノ酸配列解析方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004051281A1 true WO2004051281A1 (ja) | 2004-06-17 |
Family
ID=32462894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/015270 WO2004051281A1 (ja) | 2002-11-29 | 2003-11-28 | ペプチドのc末端アミノ酸配列解析方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US7670841B2 (ja) |
EP (1) | EP1574860A4 (ja) |
JP (1) | JP4257492B2 (ja) |
AU (1) | AU2003284493A1 (ja) |
WO (1) | WO2004051281A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4771296B2 (ja) * | 2006-02-08 | 2011-09-14 | 日本電気株式会社 | ペプチドのc末端のペプチド結合を切断する方法、及びペプチドのc末端アミノ酸配列の決定方法 |
JP4771297B2 (ja) * | 2006-02-08 | 2011-09-14 | 日本電気株式会社 | ペプチドの修飾方法及びペプチドの同定方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4631943B2 (ja) * | 2008-07-24 | 2011-02-16 | 日本電気株式会社 | ペプチドの分解方法、ペプチドの分析方法、ペプチドの分解装置、ペプチドの分析装置 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0627113A (ja) * | 1992-07-08 | 1994-02-04 | Seiko Instr Inc | タンパク質あるいはペプチドのカルボキシ末端からのアミノ酸配列を決定する方法 |
JPH10293130A (ja) * | 1996-05-24 | 1998-11-04 | Seiko Instr Inc | タンパク質あるいはペプチドのカルボキシ末端からのアミノ酸配列を決定する方法 |
JP2000146983A (ja) * | 1990-08-13 | 2000-05-26 | City Of Hope | ペプチド及び蛋白質の連続c末端分解 |
JP2002189029A (ja) * | 2000-12-21 | 2002-07-05 | Sumitomo Chem Co Ltd | タンパク質のn末端のアミノ酸配列決定方法 |
JP2003279581A (ja) * | 2002-03-25 | 2003-10-02 | Nec Corp | ペプチドのc末端アミノ酸配列解析方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521097A (en) * | 1991-08-28 | 1996-05-28 | Seiko Instruments Inc. | Method of determining amino acid sequence of protein or peptide from carboxy-terminal |
JP2686506B2 (ja) | 1991-11-15 | 1997-12-08 | セイコーインスツルメンツ株式会社 | タンパク質あるいはペプチドのカルボキシ末端からのアミノ酸配列を決定する方法 |
-
2002
- 2002-11-29 JP JP2002347777A patent/JP4257492B2/ja not_active Expired - Fee Related
-
2003
- 2003-11-28 US US10/536,824 patent/US7670841B2/en not_active Expired - Fee Related
- 2003-11-28 EP EP03775962A patent/EP1574860A4/en not_active Withdrawn
- 2003-11-28 AU AU2003284493A patent/AU2003284493A1/en not_active Abandoned
- 2003-11-28 WO PCT/JP2003/015270 patent/WO2004051281A1/ja not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000146983A (ja) * | 1990-08-13 | 2000-05-26 | City Of Hope | ペプチド及び蛋白質の連続c末端分解 |
JPH0627113A (ja) * | 1992-07-08 | 1994-02-04 | Seiko Instr Inc | タンパク質あるいはペプチドのカルボキシ末端からのアミノ酸配列を決定する方法 |
JPH10293130A (ja) * | 1996-05-24 | 1998-11-04 | Seiko Instr Inc | タンパク質あるいはペプチドのカルボキシ末端からのアミノ酸配列を決定する方法 |
JP2002189029A (ja) * | 2000-12-21 | 2002-07-05 | Sumitomo Chem Co Ltd | タンパク質のn末端のアミノ酸配列決定方法 |
JP2003279581A (ja) * | 2002-03-25 | 2003-10-02 | Nec Corp | ペプチドのc末端アミノ酸配列解析方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4771296B2 (ja) * | 2006-02-08 | 2011-09-14 | 日本電気株式会社 | ペプチドのc末端のペプチド結合を切断する方法、及びペプチドのc末端アミノ酸配列の決定方法 |
JP4771297B2 (ja) * | 2006-02-08 | 2011-09-14 | 日本電気株式会社 | ペプチドの修飾方法及びペプチドの同定方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2003284493A8 (en) | 2004-06-23 |
AU2003284493A1 (en) | 2004-06-23 |
EP1574860A4 (en) | 2007-03-14 |
JP2004184092A (ja) | 2004-07-02 |
US20060030052A1 (en) | 2006-02-09 |
EP1574860A1 (en) | 2005-09-14 |
JP4257492B2 (ja) | 2009-04-22 |
US7670841B2 (en) | 2010-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7816304B2 (en) | Mass labels | |
EP1425586B1 (en) | Mass labels | |
US8119411B2 (en) | Method for analyzing C-terminal amino acid sequence of peptide using mass spectrometry | |
AU2001240834A1 (en) | Mass labels | |
JP2008051790A (ja) | 微量質量分析法 | |
JP4102581B2 (ja) | ペプチドのc末端アミノ酸配列解析方法 | |
WO2004051281A1 (ja) | ペプチドのc末端アミノ酸配列解析方法 | |
JP4604345B2 (ja) | タンパク質のn末端のアミノ酸配列決定方法 | |
JP4289355B2 (ja) | ペプチドのc末端アミノ酸配列の分析方法 | |
JP4086642B2 (ja) | ペプチドのc末端アミノ酸配列解析方法 | |
JP2009092411A (ja) | ペプチドの同定方法 | |
CN115825201A (zh) | 一种使用毛细管电泳仪电离还原蛋白二硫键并确定其自由巯基比例的方法 | |
JP2012032416A (ja) | 微量質量分析法 | |
WO2003104813A2 (en) | Characterising polypeptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2006030052 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10536824 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003284493 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003775962 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003775962 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10536824 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003775962 Country of ref document: EP |